Clinical Professor Harry Iland
C39 - Royal Prince Alfred Hospital
His main interests have encompassed molecular abnormalities in haematological malignancies, and he established one of the earliest molecular diagnostic laboratories for haematological malignancy in Australia. In the last few years he has been responsible for the Australasian Leukaemia and Lymphoma Group’s clinical trial program in acute promyelocytic leukaemia (APL), and has combined this with an active laboratory program in the molecular analysis of APL cells. His laboratory has also established molecular assays relevant for patients with idiopathic hypereosinophilic syndrome / chronic eosinophilic leukaemia.
United Kingdom. (Kings College London) Prof David Grimwade - retinoic acid receptor ligand binding domain mutational analysis in relapsed acute promyelocytic leukaemia.
United States. (Robert H. Lurie Comprehensive Cancer Center, Northwestern University) Dr Jessica Altman - planning a multi-cooperative group trial in acute promyelocytic leukemia.
United States. (Memorial Sloan Kettering Cancer Center) Professor Martin Tallman - planning a multi-cooperative group trial in acute promyelocytic leukemia.